FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions relates to the field of medicine and pharmaceuticals. First object is a dry pharmaceutical composition containing dry particles which include particles of a pharmaceutically active agent, a pharmaceutically acceptable binder and a pharmaceutically acceptable carrier. Second and third objects are a method for preparing a dry pharmaceutical composition, including drying the aqueous suspension by spraying, and a composition produced by this method. Other objects are methods of administering an active agent, including administering a dry pharmaceutical composition, and using a dry pharmaceutical composition in the method of administering and preparing the drug.
EFFECT: technical result consists in fast delivery of an active agent, bioadhesion, better storage stability of a dry pharmaceutical composition for administration through the mucosa and containing the above dry particles.
24 cl, 8 dwg, 14 tbl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
DEAMORPHIZATION OF SPRAY-DRIED FORMULATIONS VIA SPRAY-BLENDING | 2014 |
|
RU2698331C2 |
DRY POWDER COMPOSITIONS REPRESENTED AS PARTICLES WHICH CONTAIN TWO OR MORE ACTIVE INGREDIENTS FOR TREATMENT OF OBSTRUCTIVE OR INFLAMMATORY DISEASES OF RESPIRATORY WAYS | 2012 |
|
RU2629333C2 |
AGGREGATED PARTICLES | 2013 |
|
RU2666963C2 |
AXELASTIN AND STEROIDS COMBINATION | 2003 |
|
RU2361593C2 |
DIRECTED DELIVERY OF SPRAY-DRIED COMPOSITIONS INTO THE LUNGS | 2016 |
|
RU2731212C2 |
METHOD OF PROCESSING PARTICLES OF ACTIVE PHARMACEUTICAL INGREDIENTS | 2011 |
|
RU2597790C2 |
COMPOSITIONS, METHODS AND SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS | 2010 |
|
RU2586297C2 |
TREATMENT OF ALLERGIC RHINITIS IN PEDIATRIC CATEGORY USING A COMBINATION OF MOMETASONE AND OLOPATADINE | 2019 |
|
RU2798030C2 |
INHALATION FORMULATION CONTAINING SULFOALKYL ETHER GAMMA-CYCLODEXTRIN AND CORTICOSTEROID | 2004 |
|
RU2390330C2 |
INHALATION COMPOSITION CONTAINING SULFOALKYL ETHER | 2004 |
|
RU2388462C2 |
Authors
Dates
2020-03-03—Published
2014-03-03—Filed